A Phase 3 interventional study of buntanetap/posiphen and Placebo in Parkinson's Disease, Idiopathic, sponsored by Annovis Bio Inc.. Completed at 69 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Annovis Bio Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 50th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2022, is one of 126 in phase 3, and was the 1,252nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 105 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 523 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
Annovis Bio Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Annovis Bio Inc. has 3 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
138 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 138 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD.
Study details include:
450 early Parkinson's Disease (PD) patients will be randomized to 10mg, 20 mg of buntanetap/posiphen or placebo. They will undergo a Screening Visit, and if they provide informed consent and are considered eligible per the inclusion and exclusion criteria, will proceed to participate in the treatment period. Randomized participants will visit the clinic for the first-time dosing in clinic with administration of 10 mg or 20mg of buntanetap/posiphen or placebo, followed by an at home dosing period of 6 months, with daily administration of 10 mg or 20mg of buntanetap/posiphen or Placebo. Participants will be required to visit clinics 1 month, 2 months, 3 months, and 6 months (end-of-trial), where they will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations) and psychometric tests (MDS-United Parkinson's Disease Rating Scale (MDS-UPDRS), Clinical Global Impression of Severity (CGIS), Wechsler Adult Intelligence Scales (WAIS), Mini-Mental State Examination (MMSE)) and Participant Global Impression of Change (PGIC). At the end of blood sampling, the subjects will need to stay for a minimum of 1 hour of observation. After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur after all clinical visits to assess the participants current condition and if there are any additional adverse events to report.
Buntanetap/posiphen has shown to improve PD subjects' mobility. MDS-UPDRS sum of score of Part II + Part III and Total score of all four parts will be measured to assess its improvement on PD subjects daily living, mobility and complications. PGIC will also be measured to assess its effect.
Buntanetap/posiphen has shown to reduce inflammation and preserve axonal integrity and synaptic functions as well as neurotoxic proteins in previous Phase 2a studies. In this study we plan to measure plasma glial fibrillary acidic protein (GFAP), neurofilament light (NFL) and potentially TDP43.
Reports of adverse events (AEs) and serious adverse events (SAEs) during exposure to buntanetap/posiphen will be collected to evaluate if there are any significant clinical safety issues for the study population. Extensive clinical and laboratory safety data already exist for buntanetap/posiphen; therefore, these safety measures will be sufficient in the proposed study.
For clinical, functional, and cognitive assessment measures, The subjects will be administered the Hoehn \& Yahr and the MMSE for determination of inclusion into the study. The MDS-UPDRS and PGIC will be administered for subjects' movement and daily function. The Coding subtest from the WAIS 4th edition will serve as a sensitive measure of Central Nervous System (CNS) dysfunction. MMSE will also be measured to assess subjects' cognitive change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of * must have a negative serum or urine pregnancy test at Screening, must be non-lactating and must agree to use a highly effective method of (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for 4 weeks after the last dose of trial treatment, such as:
Male subjects must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subject must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:
At screening subjects do not need to but may be on the following medication:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Buntanetap/posiphen 10 mg oral capsule with daily administration for a period of 6 months
Drug: buntanetap/posiphen
Buntanetap/posiphen 20 mg oral capsule with daily administration for a period of 6 months
Drug: buntanetap/posiphen
Placebo oral capsule with daily administration for a period of 6 months
Drug: Placebo
Drug page: Buntanetap
HPMC (vegetarian source) capsule shells
Also known as: Posiphen Tartrate, ANVS401
HPMC (vegetarian source) capsule shells
Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)
Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.
Time frame: Baseline and 6 months visits
Change From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state)
MDS-UPDRS Part III (motor examination) has 18 items and ranges from 0-132, with higher scores reflecting greater severity.
Time frame: Baseline and 6 months visits
Change From Baseline to Month 6 in MMSE (OFF-state)
Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.
Time frame: Baseline and 6 months visits
| Milestone | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Started | 176 | 174 | 173 |
| Completed | 162 | 159 | 150 |
| Not completed | 14 | 15 | 23 |
Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.
| units on a scale | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state) | -0.10 ± 0.311 | 0.57 ± 0.312 | -0.04 ± 0.319 |
MDS-UPDRS Part III (motor examination) has 18 items and ranges from 0-132, with higher scores reflecting greater severity.
| units on a scale | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Change From Baseline to Month 6 in the MDS-UPDRS Part III (OFF-state) | -2.90 ± 0.698 | -1.04 ± 0.697 | -2.66 ± 0.713 |
Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.
| units on a scale | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Change From Baseline to Month 6 in MMSE (OFF-state) | -0.39 ± 0.123 | -0.08 ± 0.123 | -0.05 ± 0.126 |
Change in the MMSE score from Baseline to the End of Trial. MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.
| units on a scale | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Change From Baseline to Month 6 in MMSE (OFF-state) for Participants With Baseline MMSE Scores 20-28 | -0.50 ± 0.317 | 0.65 ± 0.313 | 0.45 ± 0.301 |
Collected over From consent to end of trial (up to 8 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/176 (0%) | 5/176 (2.8%) | 20/176 (11.4%) |
| 10 mg Buntanetap/Posiphen | 1/174 (0.6%) | 4/174 (2.3%) | 15/174 (8.6%) |
| 20 mg Buntanetap/Posiphen | 0/173 (0%) | 11/173 (6.4%) | 24/173 (13.9%) |
| Event | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 0/176 | 2/174 | 0/173 |
| Angina PectorisCardiac disorders | 0/176 | 0/174 | 1/173 |
| Myocardial IschaemiaCardiac disorders | 0/176 | 0/174 | 1/173 |
| Accidental OverdoseInjury, poisoning and procedural complications | 0/176 | 0/174 | 1/173 |
| ContusionInjury, poisoning and procedural complications | 0/176 | 0/174 | 1/173 |
| Hip FractureInjury, poisoning and procedural complications | 0/176 | 0/174 | 1/173 |
| GastroenteritisInfections and infestations | 0/176 | 0/174 | 1/173 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/176 | 0/174 | 1/173 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/176 | 0/174 | 1/173 |
| Toxic EncephalopathyNervous system disorders | 0/176 | 0/174 | 1/173 |
| Event | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen |
|---|---|---|---|
| NauseaGastrointestinal disorders | 5/176 | 5/174 | 11/173 |
| Covid-19Infections and infestations | 10/176 | 5/174 | 4/173 |
| FatigueGeneral disorders | 5/176 | 5/174 | 9/173 |
| Age, Continuous(years) | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen | Total |
|---|---|---|---|---|
| Mean | 65.4 ± 8.88 | 65.0 ± 8.85 | 65.4 ± 10.09 | 65.2 ± 9.27 |
| Sex: Female, Male(Participants) | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen | Total |
|---|---|---|---|---|
| Female | 65 | 54 | 55 | 174 |
| Male | 111 | 120 | 118 | 349 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen | Total |
|---|---|---|---|---|
| Hispanic or Latino | 30 | 21 | 31 | 82 |
| Not Hispanic or Latino | 146 | 152 | 141 | 439 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 4 | 4 | 3 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 6 | 3 | 13 |
| White | 167 | 163 | 166 | 496 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Mini-Mental State Examination (MMSE)(units on a scale) | Placebo | 10 mg Buntanetap/Posiphen | 20 mg Buntanetap/Posiphen | Total |
|---|---|---|---|---|
| Mean | 28.7 ± 1.71 | 28.7 ± 1.70 | 28.3 ± 2.12 | 28.6 ± 1.86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Aug 2022 to primary completion in Dec 2023, 16 months.
Results were first posted in Mar 2025, 1 year 2 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 16 months is below that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buntanetap
Annovis Bio Inc.